BioSpace News Archive

Alexion said the acquisition of Portola will bolster its commercial portfolio and create long-term value for its shareholders.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.

Praxis is currently focused on leveraging its research on the genetics of epilepsy. Using its insights, the company is currently working on a pipeline of treatments that address the genes that control the imbalance of excitation and inhibition of neuronal circuitry.

Akebia Therapeutics’ investigational drug vadadustat hit the mark in the first of two Phase III trials in chronic kidney disease (CKD) patients who are on dialysis, and investors are pleased.

In an interview with National Geographic, Fauci once again sided with the evidence that indicates the virus is a species jumper and originated in the animal kingdom.

Leaders from all over the world met for a virtual summit on Monday, May 4 to pledge billions of dollars to fund development of a vaccine against COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. Noticeably absent was the United States.

In 1996, Udit Batra received his Ph.D. in chemical engineering from Princeton University. 24 years later, he heads a MilliporeSigma, $7.5 billion global life sciences company with a catalog of some 300,000 items used by life sciences researchers and developers throughout the world.

Sanofi and Regeneron are focusing on basal cell carcinoma treatment and their drug Libtayo is showing good results. The companies expect to make regulatory submissions this year.

Luminex, a developer of molecular diagnostics and clinical tools for the life sciences industry, returned to profit this quarter – well ahead of schedule – after a major client, LabCorp, departed in 2019.

i oTech International announced today that three of its products, based on patented, proprietary, non-staining formulations of molecular iodine, are being used in an IRB approved, controlled clinical trial that was just initiated at St. Joseph’s Hospital University Medical Center in Patterson, NJ. The products being evaluated are ioRi